Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA - Free Report) in a research report report published on Friday, MarketBeat.com reports. The firm issued an overweight rating and a $34.00 price target on the stock.
Several other research firms have also commented on KNSA. Wedbush reaffirmed an outperform rating and set a $30.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, April 23rd. Evercore ISI boosted their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an outperform rating in a research note on Wednesday, April 24th. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an overweight rating in a research report on Wednesday. Finally, TheStreet upgraded shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research report on Thursday, February 29th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of Buy and an average target price of $31.00.
View Our Latest Stock Report on Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Trading Up 3.6 %
Shares of KNSA stock traded up $0.70 during mid-day trading on Friday, reaching $20.08. The stock had a trading volume of 403,798 shares, compared to its average volume of 408,509. Kiniksa Pharmaceuticals has a 1-year low of $12.69 and a 1-year high of $22.09. The business's fifty day moving average is $19.16 and its 200-day moving average is $18.08. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 182.56 and a beta of 0.32.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The business had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.26%. The business's revenue was up 65.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. On average, analysts forecast that Kiniksa Pharmaceuticals will post -0.04 earnings per share for the current year.
Insiders Place Their Bets
In related news, CEO Sanj K. Patel sold 12,742 shares of the firm's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the transaction, the chief executive officer now directly owns 70,594 shares of the company's stock, valued at approximately $1,517,065.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Sanj K. Patel sold 12,742 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanj K. Patel sold 5,582 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total value of $117,222.00. Following the completion of the transaction, the chief executive officer now owns 65,012 shares in the company, valued at approximately $1,365,252. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,109 shares of company stock worth $709,929. Company insiders own 54.23% of the company's stock.
Institutional Trading of Kiniksa Pharmaceuticals
Large investors have recently bought and sold shares of the business. Granahan Investment Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company's stock valued at $12,671,000 after purchasing an additional 188,174 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in Kiniksa Pharmaceuticals by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 615,693 shares of the company's stock worth $10,799,000 after buying an additional 105,883 shares during the last quarter. Altitude Crest Partners Inc. purchased a new stake in Kiniksa Pharmaceuticals in the 4th quarter valued at $7,999,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 59.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company's stock worth $4,463,000 after acquiring an additional 96,288 shares during the last quarter. Finally, Peregrine Capital Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter worth $4,657,000. Hedge funds and other institutional investors own 53.95% of the company's stock.
Kiniksa Pharmaceuticals Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
